Risk-guided Disease managEment Plan to prevEnt CAD in Patients Treated With Previous Cancer

Last updated: November 27, 2025
Sponsor: Baker Heart and Diabetes Institute
Overall Status: Active - Recruiting

Phase

N/A

Condition

Cardiovascular Disease

Coronary Artery Disease

Vascular Diseases

Treatment

Coronary CT

Clinical Study ID

NCT05366153
134-22
  • Ages 40-70
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

REDEEM-CAD is a prospective multi-centre study of CAD risk evaluation and management in cancer survivors 40-70 years with chemotherapy or radiotherapy >5 years ago.

Eligibility Criteria

Inclusion

Inclusion Criteria:

A history of cancer >5 y ago associated with potential cardiotoxicity from chemotherapy and/or radiotherapy (chiefly survivors of breast cancer, Hodgkin's lymphoma and prostate cancer).

Exclusion

Exclusion Criteria:

  • Unable to provide written informed consent to participate in this study

  • Known coronary artery disease at recruitment

  • History of previous coronary artery disease

  • Inability to acquire interpretable CT images

  • Contraindications/Intolerance to or already taking statin therapy

  • Oncologic (or other) life expectancy <12 months or any other medical condition (including pregnancy) that results in the belief (deemed by the Chief Investigators)that it is not appropriate for the patient to participate in this trial

Study Design

Total Participants: 748
Treatment Group(s): 1
Primary Treatment: Coronary CT
Phase:
Study Start date:
October 18, 2023
Estimated Completion Date:
May 31, 2026

Study Description

REDEEM-CAD is a prospective multi-centre study in which a process of evaluating the risk of coronary artery disease is studied in cancer survivors 40-70 years with chemotherapy or radiotherapy >5 years ago. The efficacy of this CAD risk evaluation will be compared with the broad community in two existing studies - CAUGHT-CAD and EDCAD. This unique Screening/Management Plan (SMP) has 2 components; 1) A novel clinical and imaging-based screening algorithm to select those most likely to develop coronary artery disease, 2) A clinical review to ensure optimal risk factor control and cardio protection.

Follow-up of treated patients will continue for an average of 36 months, with clinic reviews at 12, 24 and 36 months. The results will define the prevalence of subclinical coronary artery disease, and the feasibility and the efficacy of the SMP.

Connect with a study center

  • Tom Marwick

    Hobart, Tasmania 7000
    Australia

    Site Not Available

  • Tom Marwick

    Hobart 2163355, Tasmania 2147291 7000
    Australia

    Active - Recruiting

  • Baker Heart and Diabetes Institute

    Melbourne, Victoria 3004
    Australia

    Site Not Available

  • Baker Heart and Diabetes Institute

    Melbourne 2158177, Victoria 2145234 3004
    Australia

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.